Review on Drug Resistant Tuberculosis
Loading...
Date
2022-08
Journal Title
Journal ISSN
Volume Title
Publisher
Prathima Institute of Medical Sciences
Abstract
Introduction: An estimated 9.9 million people fell ill with tuberculosis globally in 2020 with India and China contribu?ng a major percentage to the burden of TB. India is grouped under high TB, high HIV associated TB and MDR TB burden countries and 1.24 lakh fell ill with drug resistant TB out of which 56000 were started on second line treatment in 2020. Annually India accounts for 27% of missing TB cases. Diagnosis: The major forms of drug resistant TB that are of clinical importance are INH monoresistant TB, mul?drug resistant TB, pre- XDR TB and XDR TB.WHO approved newer molecular tests for MTB detec?on and drug suscep?bility tests. Treatment: Few newer drugs and few previously used drugs are showing promise when used in combina?on which have come up in recent years. Bedaquiline based regimens are showing improved cure rates. Conclusion: Guidelines based regimens should be strictly adhered to by both public and private TB case trea?ng physicians.
Description
Keywords
Multi drug resistant tuberculosis (MDR TB), Molecular tests for tuberculosis, Programma?c management of Drug resistant tuberculosis (PMDT), Bedaquiline.
Citation
Chenimilla Nagender Prasad, Pittala Pravinya, Madire Ramulu. Review on Drug Resistant Tuberculosis. Prathima Institute of Medical Sciences. 2022 Aug; 10(2): 2-8